In our article entitled, “Long-term survival in a child with severe encephalopathy, multiple respiratory chain deficiency and GFM1 mutations,” published in Frontiers in Genetics on 23rd March 2015 we inadvertently omitted information that the attending paediatrician believes may be relevant to the case. In the interests of accuracy and completeness we would like to add that the patient we describe had been receiving treatment with Ubiquinone (20 mg/day), Riboflavin (100 mg/day), Carnitine (500 mg/day), N-acetylcysteine (100 mg/day), and Folinic acid (15 mg/day) for 6 months prior to inclusion in the report. While there was no obvious improvement in her condition, equally she has not exhibited any further clinical deterioration since treatment began. Radiological progression was, however, evident on a cranial MRI performed 5 months after treatment was initiated. Given the relatively short duration of treatment (approximately 6 months at the time of writing the report) and the neuroradiological progression evident on the repeat cranial MRI, we consider it unlikely that this vitamin and antioxidant treatment has made a substantial contribution to the patient's longer survival.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.